Metastatic Breast Cancer Clinical Trial
Official title:
Randomized Controlled Trial Assessing the Impact of Routine "Oncologist-supportive Care Team" Consultation on the Use of an Additional Line of Chemotherapy in Metastatic Breast Cancer Patients
The purpose of this study is to assess the impact of systematic "clinical cancer
department/supportive care department" consultation meetings, versus standard care, on the
prescription of an additional line of chemotherapy in patients with metastatic breast cancer
and visceral involvement after 3 or 4 lines of chemotherapy.
This is a prospective paucicentric open label randomized controlled study with 2 parallel
arms.
Eligible patients will be randomly assigned to either arm "Study group" or "Standard care".
The number of patients required to demonstrate a 30% reduction of the number of
prescriptions for an additional line chemotherapy, assuming an alpha risk of 5% and 80%
power, is 100 (50 in each arm).
The hypothesis tested is that systematic routine consultation between the supportive care
team and clinical oncologists will allow more efficient utilization of supportive care by
metastatic breast cancer patients, and will reduce the isolation of physicians involved in
the management of these patients. Physicians will then be able to help the patients make
realistic decisions for the best possible quality of life and in full accordance with their
preferences.
The DISSPO (Department of Interdisciplinary Supportive Care for Cancer Patients) focuses on
psycho-oncology, pain evaluation and treatment, palliative care, social service, dietary
guidance and physiotherapy. Usually, visits with the DISSPO are arranged when the patients
need supportive care but are not included in routine care. In this study, contacts between
clinical oncologists and supportive care staff will be formalized and systematized. A
specific visit called "supportive care visit" will be organized to investigate the needs of
the patient so that a personalized care plan can be proposed. Moreover, a consultation
between the referring oncologist and the DISSPO will be organized at least once a month.
Besides the main objective of this study (see brief summary), there are secondary objectives
which are to evaluate the impact of systematic "Clinical cancer department/Supportive care
department" consultation meetings versus standard care on:
- the use of supportive care
- symptom control
- anxiety-depression levels
- quality of life
- patient representations (adaptation to the disease and locus of control)
- patient perception of social support
- patient satisfaction with the care
- impact of disease on the family
- satisfaction of the referring oncologist
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04872608 -
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02506556 -
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05534438 -
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03368729 -
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04103853 -
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Active, not recruiting |
NCT03147287 -
Palbociclib After CDK and Endocrine Therapy (PACE)
|
Phase 2 | |
Not yet recruiting |
NCT06062498 -
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04095390 -
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04432454 -
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
|
Phase 2 | |
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
Completed |
NCT02924883 -
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
|
Phase 2 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Completed |
NCT01942135 -
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
|
Phase 3 | |
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT01401959 -
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT04720664 -
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
|
Phase 2 |